Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Omicron BA. 1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
J Quandt, A Muik, N Salisch, BG Lui, S Lutz… - Science …, 2022 - science.org
Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA. 1 breakthrough …
(SARS-CoV-2) variant of concern (VOC) to date. We report that Omicron BA. 1 breakthrough …
Antibodies to combat viral infections: development strategies and progress
G Pantaleo, B Correia, C Fenwick, VS Joo… - Nature Reviews Drug …, 2022 - nature.com
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously
evolving, and this poses a major threat to antibody therapies and currently authorized …
evolving, and this poses a major threat to antibody therapies and currently authorized …
[PDF][PDF] Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern
Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) can transmit more efficiently and partially evade protective immune …
(SARS-CoV-2) can transmit more efficiently and partially evade protective immune …
Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA. 1, BA. 2, and BA. 4/5 and diverse sarbecoviruses
M Li, Y Ren, ZQ Aw, B Chen, Z Yang, Y Lei… - Nature …, 2022 - nature.com
Abstract As SARS-CoV-2 Omicron and other variants of concern (VOCs) continue spreading
worldwide, development of antibodies and vaccines to confer broad and protective activity is …
worldwide, development of antibodies and vaccines to confer broad and protective activity is …
Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection
R Wang, Y Han, R Zhang, J Zhu, X Nan, Y Liu, Z Yang… - Immunity, 2023 - cell.com
The 2003 severe acute respiratory syndrome coronavirus (SARS-CoV-1) causes more
severe disease than SARS-CoV-2, which is responsible for COVID-19. However, our …
severe disease than SARS-CoV-2, which is responsible for COVID-19. However, our …
[PDF][PDF] Cryo-EM structure of the SARS-CoV-2 Omicron spike
Summary The recently reported B. 1.1. 529 Omicron variant of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) includes 34 mutations in the spike protein relative to …
syndrome coronavirus-2 (SARS-CoV-2) includes 34 mutations in the spike protein relative to …